Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) Receives Consensus Rating of “Moderate Buy” from Analysts

Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) has been given an average recommendation of “Moderate Buy” by the fifteen ratings firms that are covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and thirteen have issued a buy recommendation on the company. The average 12 month price objective among brokers that have issued ratings on the stock in the last year is $19.4545.

ORIC has been the subject of several analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Oric Pharmaceuticals in a report on Friday, July 17th. Stifel Nicolaus initiated coverage on shares of Oric Pharmaceuticals in a report on Friday, June 12th. They set a “buy” rating and a $14.00 target price on the stock. Benchmark restated a “buy” rating on shares of Oric Pharmaceuticals in a research report on Monday, June 8th. HC Wainwright raised their price target on Oric Pharmaceuticals from $25.00 to $27.00 and gave the stock a “buy” rating in a report on Monday, August 10th. Finally, Wall Street Zen raised Oric Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Saturday, July 25th.

Oric Pharmaceuticals Stock Performance

ORIC stock opened at $13.87 on Monday. The stock has a market cap of $1.44 billion, a P/E ratio of -10.27 and a beta of 1.02. The stock’s fifty day simple moving average is $10.72 and its two-hundred day simple moving average is $10.52. Oric Pharmaceuticals has a 1-year low of $7.23 and a 1-year high of $14.93.

Oric Pharmaceuticals (NASDAQ:ORIC) last issued its earnings results on Monday, August 3rd. The company reported ($0.38) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.02). As a group, analysts forecast that Oric Pharmaceuticals will post -1.53 earnings per share for the current fiscal year.

Institutional Trading of Oric Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in ORIC. Federation des caisses Desjardins du Quebec grew its holdings in Oric Pharmaceuticals by 100.0% during the 4th quarter. Federation des caisses Desjardins du Quebec now owns 4,000 shares of the company’s stock valued at $33,000 after buying an additional 2,000 shares in the last quarter. Caitong International Asset Management Co. Ltd lifted its holdings in shares of Oric Pharmaceuticals by 184.4% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 4,528 shares of the company’s stock worth $37,000 after buying an additional 2,936 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of Oric Pharmaceuticals by 26.0% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,732 shares of the company’s stock worth $39,000 after buying an additional 977 shares in the last quarter. Quantbot Technologies LP bought a new position in shares of Oric Pharmaceuticals in the second quarter valued at approximately $46,000. Finally, Russell Investments Group Ltd. bought a new position in shares of Oric Pharmaceuticals in the third quarter valued at approximately $60,000. Hedge funds and other institutional investors own 95.05% of the company’s stock.

About Oric Pharmaceuticals

Oric Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California. The firm is dedicated to discovering and developing small molecule therapeutics designed to overcome resistance mechanisms in solid tumor oncology. Its research efforts focus on identifying novel targets and advancing precision medicines that can restore or enhance patient response when standard therapies fail.

The company’s pipeline features lead candidates such as ORIC-101, a selective, orally available antagonist of the glucocorticoid receptor currently being evaluated in Phase 1/2 trials for patients with solid tumors who have acquired resistance to chemotherapy and hormonal agents.